// Auto-generated - do not edit
export const substanceName = "3-HO-PCE";
export const sources = [{"id":"isomerdesign","fileName":"ISOMERDESIGN - 3-HO-PCE.md","displayName":"Isomer Design","size":676},{"id":"protestkit","fileName":"PROTESTKIT - 3-HO-PCE.json","displayName":"Protest Kit","size":6328},{"id":"psychonautwiki","fileName":"PSYCHONAUTWIKI - 3-HO-PCE.md","displayName":"PsychonautWiki","size":23690},{"id":"tripsit-factsheets","fileName":"TRIPSIT_FACTSHEETS - 3-HO-PCE.md","displayName":"TripSit Factsheets","size":378},{"id":"wikipedia","fileName":"WIKIPEDIA - 3-HO-PCE.md","displayName":"Wikipedia","size":2280}];
export const contents: Record<string, string> = {
  "isomerdesign": `# 3-HO-PCE
*Source: https://isomerdesign.com/PiHKAL/explore.php?id=968*

## Chemical Data

**Names:** 3-HO-PCE, 3-Hydroxyeticyclidine

**IUPAC Name:** 3-[1-(Ethylamino)cyclohexyl]phenol

**Molecular Formula:** C14H21NO

**Molecular Weight:** 219.323

**SMILES:** \`CCNC1(CCCCC1)c1cccc(c1)O\`

**InChI:** \`InChI=1S/C14H21NO/c1-2-15-14(9-4-3-5-10-14)12-7-6-8-13(16)11-12/h6-8,11,15-16H,2-5,9-10H2,1H3\`

## External References

- [](https://en.wikipedia.org/wiki/Markush_structure)
- [81367248](https://www.chemspider.com/Chemical-Structure.81367248.html/)
- [137332171](https://pubchem.ncbi.nlm.nih.gov/compound/137332171)
- [Q126606830](https://www.wikidata.org/wiki/Q126606830)
`,
  "protestkit": `{
  "url": "https://psychonautwiki.org/wiki/3-HO-PCE",
  "experiencesUrl": "https://www.reddit.com/search/?q=3-HO-PCE",
  "name": "3-HO-PCE",
  "aliases": [
    "3hopce",
    "hydroxyeticyclidine"
  ],
  "aliasesStr": "3hopce,hydroxyeticyclidine",
  "summary": "A rare and very potent PCP analogue, eight times more potent than PCP as NMDA receptor antagonist and also a μ-opioid receptor agonist. Similar in structure to methoxetamine.",
  "reagents": null,
  "classes": {
    "chemical": [],
    "psychoactive": [
      "Opioids"
    ]
  },
  "toxicity": [
    "toxic dosage is unknown"
  ],
  "addictionPotential": "moderately addictive with a moderate potential for adverse side effects such as psychosis",
  "tolerance": {
    "full": "with prolonged and repeated use",
    "half": "4 - 7 days",
    "zero": "1 - 2 weeks"
  },
  "crossTolerances": [
    "dissociative"
  ],
  "roas": [
    {
      "name": "Oral",
      "dosage": [
        {
          "name": "Threshold",
          "value": "5 mg"
        },
        {
          "name": "Light",
          "value": "5 - 10 mg"
        },
        {
          "name": "Common",
          "value": "10 - 15 mg"
        },
        {
          "name": "Strong",
          "value": "15 - 25 mg"
        },
        {
          "name": "Heavy",
          "value": "25 mg +",
          "note": "Redosing may result in dangerous cumulative effects."
        }
      ],
      "duration": [
        {
          "name": "Total",
          "value": "4.0 - 6.0 hours"
        }
      ]
    }
  ],
  "interactions": [
    {
      "name": "2C-T-x",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "2C-x",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "5-MeO-xxT",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Alcohol",
      "status": "Dangerous"
    },
    {
      "name": "Amphetamines",
      "status": "Caution"
    },
    {
      "name": "Benzos",
      "status": "Dangerous"
    },
    {
      "name": "Caffeine",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Cannabis",
      "status": "Low Risk & Synergy"
    },
    {
      "name": "Cocaine",
      "status": "Dangerous"
    },
    {
      "name": "DMT",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "DOx",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "DXM",
      "status": "Dangerous"
    },
    {
      "name": "GHB/GBL",
      "status": "Dangerous"
    },
    {
      "name": "Gabapentinoids",
      "status": "Dangerous"
    },
    {
      "name": "Ketamine",
      "status": "Dangerous"
    },
    {
      "name": "LSD",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "MAOIs",
      "status": "Caution"
    },
    {
      "name": "MDMA",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "MMC class",
      "status": "Unsafe"
    },
    {
      "name": "MXE",
      "status": "Dangerous"
    },
    {
      "name": "Mescaline",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Mushrooms",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "NBOMes",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Nitrous",
      "status": "Caution"
    },
    {
      "name": "PDA5",
      "status": "Unsafe"
    },
    {
      "name": "PVP class",
      "status": "Unsafe"
    },
    {
      "name": "Poppers",
      "status": "Dangerous"
    },
    {
      "name": "SSRIs",
      "status": "Low Risk & No Synergy"
    },
    {
      "name": "Tramadol",
      "status": "Dangerous"
    }
  ],
  "effects": "Auditory hallucination, Auditory distortion, Pattern recognition suppression, Scenery slicing, Perspective distortion, Cognitive disconnection, Physical disconnection, Dehydration, Difficulty urinating, Dizziness, Changes in felt gravity, Physical autonomy, Internal hallucination, Settings, sceneries, and landscapes, Time distortion, Conceptual thinking, Scenarios and plots, Delusion, Cognitive euphoria, Visual disconnection, Thought deceleration, Thought disorganization, Memory suppression, Disinhibition, Stimulation, Tactile suppression, Sedation, Appetite suppression, Respiratory depression, Pain relief, Increased heart rate, Increased blood pressure, Increased perspiration, Anxiety suppression, Increased music appreciation, Olfactory hallucination, Seizure, Depersonalization, Compulsive redosing, Derealization, Amnesia, Visual acuity suppression, Psychosis, Spatial disorientation, Optical sliding, Mania, Perspective hallucination, Immersion intensification, Tactile intensification, Auditory acuity suppression, Visual processing deceleration",
  "categorized_effects": {
    "Physical effects": [
      "Dehydration",
      "Difficulty urinating",
      "Dizziness",
      "Stimulation",
      "Sedation",
      "Appetite suppression",
      "Respiratory depression",
      "Pain relief",
      "Increased heart rate",
      "Increased blood pressure",
      "Increased perspiration",
      "Seizure"
    ],
    "Mental effects": [
      "Pattern recognition suppression",
      "Cognitive disconnection",
      "Physical disconnection",
      "Internal hallucination",
      "Time distortion",
      "Conceptual thinking",
      "Delusion",
      "Cognitive euphoria",
      "Thought deceleration",
      "Thought disorganization",
      "Memory suppression",
      "Disinhibition",
      "Anxiety suppression",
      "Increased music appreciation",
      "Depersonalization",
      "Derealization",
      "Amnesia",
      "Psychosis",
      "Spatial disorientation",
      "Mania",
      "Immersion intensification"
    ],
    "Sensory effects": [
      "Auditory hallucination",
      "Auditory distortion",
      "Scenery slicing",
      "Perspective distortion",
      "Changes in felt gravity",
      "Visual disconnection",
      "Tactile suppression",
      "Olfactory hallucination",
      "Visual acuity suppression",
      "Optical sliding",
      "Perspective hallucination",
      "Tactile intensification",
      "Auditory acuity suppression",
      "Visual processing deceleration"
    ],
    "Uncategorized effects": [
      "Physical autonomy",
      "Settings",
      "sceneries",
      "and landscapes",
      "Scenarios and plots",
      "Compulsive redosing"
    ]
  }
}`,
  "psychonautwiki": `# 3-HO-PCE
*Source: https://psychonautwiki.org/wiki/3-HO-PCE*

## Dosage & Duration

### Oral

**Dosage:**
- Threshold: 5 mg
- Light: 5 - 10 mg
- Common: 10 - 15 mg
- Strong: 15 - 25 mg
- Heavy: 25 mg + 
 Redosing may result in dangerous cumulative effects.

**Duration:**
- Total: 4 - 6 hours

**3-Hydroxyeticyclidine** (commonly known as **3-HO-PCE** ) is a novel synthetic [dissociative](https://psychonautwiki.org/wiki/Dissociative) substance of the [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) chemical class. It produces potent, dose-sensitive [dissociative](https://psychonautwiki.org/wiki/Dissociative) , [hallucinogenic](https://psychonautwiki.org/wiki/Hallucinogenic) and [euphoric](https://psychonautwiki.org/wiki/Euphoric) effects when [administered](https://psychonautwiki.org/wiki/Routes_of_administration) . Unlike its close structural analog [3-HO-PCP](https://psychonautwiki.org/wiki/3-HO-PCP) , this compound has no precedent in the scientific literature before being offered on the research chemicals market in the 2010s.

Early discussions of this compound have revolved around whether it possesses an appreciable affinity for the [μ-opioid](https://psychonautwiki.org/wiki/%CE%9C-opioid) [receptor](https://psychonautwiki.org/wiki/Receptor) given its structural relationship to [3-HO-PCP](https://psychonautwiki.org/wiki/3-HO-PCP) , which has been shown to display affinity for the [μ-opioid](https://psychonautwiki.org/wiki/%CE%9C-opioid) [receptor](https://psychonautwiki.org/wiki/Receptor) in animal models. Whether it produces any of its theorized [opioid](https://psychonautwiki.org/wiki/Opioid) effects in humans is the subject of ongoing discussion. If it does, 3-HO-PCE may pose unique risks relative to other dissociatives, particularly when it is redosed.

Following other substances of its class, particularly [methoxetamine](https://psychonautwiki.org/wiki/Methoxetamine) (MXE), [phencyclidine](https://psychonautwiki.org/wiki/Phencyclidine) (PCP), and [3-MeO-PCE](https://psychonautwiki.org/wiki/3-MeO-PCE) , it is speculated to to be able to induce a state known as " [dissociative anesthesia](https://psychonautwiki.org/wiki/Dissociatives#Subjective_effects) ". Early reports suggest that this state is difficult to reach relative to other [dissociatives](https://psychonautwiki.org/wiki/Dissociatives) , and its general effects profile has been characterized as "lying halfway between [3-MeO-PCP](https://psychonautwiki.org/wiki/3-MeO-PCP) and [3-MeO-PCE](https://psychonautwiki.org/wiki/3-MeO-PCE) ."

There is a lack of data of the pharmacological properties, metabolism and toxicity of 3-HO-PCE. To date, there have been no analytical studies conducted on samples of 3-HO-PCE distributed through the grey market via independent laboratories. Due to an unknown toxicity profile and likely similar habit-forming properties shared by other hydroxylanated arylcyclohexylamines, it is strongly recommended that one use proper [harm reduction practices](https://psychonautwiki.org/wiki/Harm_reduction_practices) if choosing to use this substance.

## History and culture

On October 18, 2012 the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, which includes 3-HO-PCE.

## Chemistry

3-HO-PCE, or 3-hydroxyeticyclidine, is a synthetic dissociative of the [arylcyclohexylamine](https://psychonautwiki.org/wiki/Arylcyclohexylamine) class. The structure of 3-HO-PCE is comprised of cyclohexane, a six-member saturated ring, bonded to two additional groups at R 1 . One of these an ethyl chain bonded at its nitrogen group. The other ring is an aromatic phenyl ring, substituted at R 3 with a hydroxy group.

3-HO-PCE is an analog of [PCE](https://psychonautwiki.org/wiki/PCE) and structurally homologous to [3-MeO-PCE](https://psychonautwiki.org/wiki/3-MeO-PCE) .

## Pharmacology

While no formal studies have been conducted, 3-HO-PCE likely acts principally as an [NMDA receptor antagonist](https://psychonautwiki.org/wiki/NMDA_receptor_antagonist) .

The NMDA (N-Methyl-D-Aspartate) receptor, a specific subtype of [glutamate](https://psychonautwiki.org/wiki/Glutamate) receptor, modulates the transmission of electrical signals between neurons in the brain and spinal cord; for the signals to pass, the receptor must be open.

Dissociatives inhibit the normal functioning NMDA receptors by binding to and blocking them. This disruption of neural network activity leads to loss of normal cognitive and affective processing, psychomotor functioning, anesthesia. [*[citation needed](https://psychonautwiki.org/wiki/Citation_needed)*]

There is ongoing speculation as to whether this compound possesses [μ-opioid](https://psychonautwiki.org/wiki/%CE%9C-opioid) receptor activity due to its structural relationship to 3-HO-PCP, which has been found to have appreciable affinity as a [μ-opioid](https://psychonautwiki.org/wiki/%CE%9C-opioid) [receptor](https://psychonautwiki.org/wiki/Receptor) [agonist](https://psychonautwiki.org/wiki/Agonist) in animal models.

## Subjective effects

***Disclaimer:** The effects listed below cite the [Subjective Effect Index](https://psychonautwiki.org/wiki/Subjective_effect_index) ( **SEI** ), an open research literature based on anecdotal user reports and the personal analyses of [PsychonautWiki](https://psychonautwiki.org/wiki/PsychonautWiki) [contributors](https://psychonautwiki.org/wiki/Special:TopUsers) . As a result, they should be viewed with a healthy degree of skepticism.*

*It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. *Likewise, **adverse effects** become increasingly likely with higher doses and may include **addiction, severe injury, or death*** ☠.*
### Physical effects
 
- The physical effects of this substance have been reported to be relatively unpronounced or difficult to detect. 
- **[Stimulation](https://psychonautwiki.org/wiki/Stimulation)** & **[Sedation](https://psychonautwiki.org/wiki/Sedation)**
- **[Tactile enhancement](https://psychonautwiki.org/wiki/Tactile_enhancement)** & **[Tactile suppression](https://psychonautwiki.org/wiki/Tactile_suppression)** - At lower dosages, this compound tends to induce tactile enhancements. At higher dosages, this enhancement shifts towards tactile suppressions and [anesthesia](https://psychonautwiki.org/wiki/Pain_relief) .
- **[Pain relief](https://psychonautwiki.org/wiki/Pain_relief)** - This substance produces distinct nerve-signal blocking anesthetic effects typically required in surgical settings, but only at higher doses.
- **[Motor control loss](https://psychonautwiki.org/wiki/Motor_control_loss)**
- **[Changes in felt gravity](https://psychonautwiki.org/wiki/Changes_in_felt_gravity)**
- **[Spatial disorientation](https://psychonautwiki.org/wiki/Spatial_disorientation)** - In contrast to other dissociatives like ketamine, this effect is only prominent at high doses.
- **[Increased blood pressure](https://psychonautwiki.org/wiki/Increased_blood_pressure)**
- **[Increased heart rate](https://psychonautwiki.org/wiki/Increased_heart_rate)**
- **[Increased perspiration](https://psychonautwiki.org/wiki/Increased_perspiration)**
- **[Respiratory depression](https://psychonautwiki.org/wiki/Respiratory_depression)**
- **[Physical autonomy](https://psychonautwiki.org/wiki/Physical_autonomy)**
- **[Olfactory hallucinations](https://psychonautwiki.org/wiki/Olfactory_hallucinations)**
- **[Optical sliding](https://psychonautwiki.org/wiki/Optical_sliding)**
- **[Appetite suppression](https://psychonautwiki.org/wiki/Appetite_suppression)**
- **[Dehydration](https://psychonautwiki.org/wiki/Dehydration)**
- **[Dizziness](https://psychonautwiki.org/wiki/Dizziness)**
- **[Difficulty urinating](https://psychonautwiki.org/wiki/Difficulty_urinating)**
- **[Seizure](https://psychonautwiki.org/wiki/Seizure)** - This extent to which this effect can be produced is unknown but can likely happen in those predisposed to them, especially while in physically taxing conditions such as being dehydrated, undernourished, overheated, or fatigued. ### Disconnective effects
 
- The disconnective effects of this compound appear to be less prominent compared to dissociatives like [ketamine](https://psychonautwiki.org/wiki/Ketamine) or [MXE](https://psychonautwiki.org/wiki/MXE) . They seem to not occur at common doses and may only occur at levels that may be accompanied by potentially dangerous side effects. 
- **[Tactile disconnection](https://psychonautwiki.org/wiki/Tactile_disconnection)**
- **[Visual disconnection](https://psychonautwiki.org/wiki/Visual_disconnection)**
- **[Consciousness disconnection](https://psychonautwiki.org/wiki/Consciousness_disconnection)** ### Cognitive effects
 
- - **[Anxiety suppression](https://psychonautwiki.org/wiki/Anxiety_suppression)**
- **[Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing)** - This effect is more prominent based on the route of administration used. For example, it is especially present when smoked or vaporized, due to the relative abruptness of the substance entering and leaving the bloodstream.
- **[Conceptual thinking](https://psychonautwiki.org/wiki/Conceptual_thinking)**
- **[Mania](https://psychonautwiki.org/wiki/Mania)** - This effect is reportedly more common on 3-HO-PCE than most other dissociatives.
- **[Depersonalization](https://psychonautwiki.org/wiki/Depersonalization)**
- **[Derealization](https://psychonautwiki.org/wiki/Derealization)**
- **[Disinhibition](https://psychonautwiki.org/wiki/Disinhibition)**
- **[Psychosis](https://psychonautwiki.org/wiki/Psychosis)**
- **[Delusion](https://psychonautwiki.org/wiki/Delusion)**
- **[Cognitive euphoria](https://psychonautwiki.org/wiki/Cognitive_euphoria)**
- **[Memory suppression](https://psychonautwiki.org/wiki/Memory_suppression)** 
- **[Ego death](https://psychonautwiki.org/wiki/Ego_death)**
- **[Amnesia](https://psychonautwiki.org/wiki/Amnesia)**
- **[Immersion enhancement](https://psychonautwiki.org/wiki/Immersion_enhancement)**
- **[Increased music appreciation](https://psychonautwiki.org/wiki/Increased_music_appreciation)**
- **[Time distortion](https://psychonautwiki.org/wiki/Time_distortion)**
- **[Thought deceleration](https://psychonautwiki.org/wiki/Thought_deceleration)**
- **[Thought disorganization](https://psychonautwiki.org/wiki/Thought_disorganization)** ### Auditory effects
 
- - **[Suppression](https://psychonautwiki.org/wiki/Auditory_suppression)**
- **[Distortions](https://psychonautwiki.org/wiki/Auditory_distortion)**
- **[Hallucinations](https://psychonautwiki.org/wiki/Auditory_hallucinations)** ### Visual effects
 
- - **[Visual acuity suppression](https://psychonautwiki.org/wiki/Visual_acuity_suppression)** - While lower doses of this compound may produce mild visual acuity enhancements, this effect quickly disappears as one's general visual faculties become suppressed as the dose is increase.
- **[Frame rate suppression](https://psychonautwiki.org/wiki/Frame_rate_suppression)**
- **[Pattern recognition suppression](https://psychonautwiki.org/wiki/Pattern_recognition_suppression)**
 
#### Distortions
 
- **[Perspective distortions](https://psychonautwiki.org/wiki/Perspective_distortions)**
- **[Scenery slicing](https://psychonautwiki.org/wiki/Scenery_slicing)**
 
#### Hallucinatory states
 
- **[Internal hallucination](https://psychonautwiki.org/wiki/Internal_hallucination)** ( *[settings, sceneries, and landscapes](https://psychonautwiki.org/wiki/Settings,_sceneries,_and_landscapes)* ; *[perspective hallucinations](https://psychonautwiki.org/wiki/Perspective_hallucinations)* and *[scenarios and plots](https://psychonautwiki.org/wiki/Scenarios_and_plots)* )
### Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our [experience index](https://psychonautwiki.org/wiki/Experience_index) . Additional experience reports can be found here:

- [Erowid Experience Vaults: 3-HO-PCE](https://www.erowid.org/experiences/subs/exp_3HOPCE.shtml)

## Toxicity and harm potential

The toxicity and long-term health effects of recreational 3-HO-PCE use has not been studied in any scientific context and the exact toxic dosage is unknown. This is because 3-HO-PCE has a very short history of human usage.

### Tolerance and addiction potential

Early reports have characterized the chronic use of 3-HO-PCE as moderately addictive with a moderate potential for adverse side effects such as psychosis. In comparison to other [dissociatives](https://psychonautwiki.org/wiki/Dissociatives) , 3-HO-PCE has been reported to be more potentially habit-forming than [MXE](https://psychonautwiki.org/wiki/MXE) , [diphenidine](https://psychonautwiki.org/wiki/Diphenidine) , [ephenidine](https://psychonautwiki.org/wiki/Ephenidine) , [DCK](https://psychonautwiki.org/wiki/DCK) , and [ketamine](https://psychonautwiki.org/wiki/Ketamine) . When addiction has developed, cravings and [withdrawal effects](https://psychonautwiki.org/wiki/Withdrawal_effects) may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 3-HO-PCE is expected to develop with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 4 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 3-HO-PCE presents cross-tolerance with all [dissociatives](https://psychonautwiki.org/wiki/Dissociative) , meaning that after the consumption of 3-HO-PCE, all [dissociatives](https://psychonautwiki.org/wiki/Dissociatives) will have a reduced effect.

It is strongly recommended that one exercise extreme caution and [harm reduction](https://psychonautwiki.org/wiki/Responsible_drug_use) practices when using this substance.

- Users should avoid taking the drug multiple days in a row or becoming dependent/addicted to it as this seems to be the main common factor in the observed incidences of severe adverse effects.
- The recommended dosage range should not be exceeded as high doses can trigger these effects as well.
- Users should start with extremely low doses and work their way up as slowly as possible. [Volumetric liquid dosing](https://psychonautwiki.org/wiki/Volumetric_liquid_dosing) should preferably be used due to the substance's potency; most standard milligram scales cannot accurately weigh out doses below 10-15mg.
- [Compulsive redosing](https://psychonautwiki.org/wiki/Compulsive_redosing) before one has fully sobered up is not recommended and can result in too high of a dose, which can potentially produce serious adverse physical side effects.

Due to the risk of psychosis, it is not recommended to combine this drug with other substances, especially [stimulants](https://psychonautwiki.org/wiki/Stimulants) , [psychedelics](https://psychonautwiki.org/wiki/Psychedelics) , or other [dissociatives](https://psychonautwiki.org/wiki/Dissociatives) . [Independent research](https://www.google.com/) should always be done to ensure that a combination of two or more substances is safe before consumption.

### Urinary tract effects

In terms of its long-term health effects when used repeatedly and excessively for extended periods of time, 3-HO-PCE is likely to exhibit similar bladder and urinary tract problems to those produced by [ketamine](https://psychonautwiki.org/wiki/Ketamine) , albeit to a lesser extent. This has been speculated to be due to the fact 3-HO-PCE is far more potent than ketamine so significantly less of material needs to be consumed. Symptoms of dissociative-induced cystitis can become extremely serious and can be described as:

- **Urinary frequency** - Urinary frequency is the need to empty the bladder every few minutes.
- **Urinary urgency** - This can be described as a sudden, compelling need to urinate.
- **Urinary pressure** - This is experienced as a constant sensation of fullness in the bladder that is unrelieved by urination.
- **Pelvic and bladder pain** - Pain can develop suddenly and severely, particularly as the bladder fills with urine.
- **Hematuria** - This is visible blood in the urine.
- **Incontinence** - This is the leakage of urine.

### Dangerous interactions

- **Stimulants** - Both stimulants and dissociatives carry the risk of adverse psychological reactions like [anxiety](https://psychonautwiki.org/wiki/Anxiety) , [mania](https://psychonautwiki.org/wiki/Mania) , [delusions](https://psychonautwiki.org/wiki/Delusions) and [psychosis](https://psychonautwiki.org/wiki/Psychosis) and these risks are exacerbated when the two substances are combined.
- **Depressants** - Because both depress the respiratory system, this combination can result in an increased risk of suddenly falling unconscious, vomiting and choking to death from the resulting suffocation. If [nausea](https://psychonautwiki.org/wiki/Nausea) or vomiting occurs, users should attempt to fall asleep in the [recovery position](https://psychonautwiki.org/wiki/Recovery_position) or have a friend move them into it.

## Legal status

- **Germany:** 3-HO-PCE is controlled under the NpSG ( *New Psychoactive Substances Act* ) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- **Sweden** : 3-HO-PCE is not a controlled substance for research purposes. It is illegal to consume.
- **Switzerland:** 3-HO-PCE is a controlled substance specifically named under Verzeichnis E.
- **Turkey:** 3-HO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.
- **United Kingdom:** 3-HO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As a derivative of 1-Phenylcyclohexylamine where the amine has been replaced with a 1-piperidyl group, further substituted in the phenyl ring with a hydroxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.

## See also

- [Responsible use](https://psychonautwiki.org/wiki/Responsible_use) 
- [Volumetric dosing](https://psychonautwiki.org/wiki/Volumetric_dosing)
- [Research chemical](https://psychonautwiki.org/wiki/Research_chemical)
- [Dissociatives](https://psychonautwiki.org/wiki/Dissociatives)
- [Arylcyclohexylamines](https://psychonautwiki.org/wiki/Arylcyclohexylamines)
- [3-MeO-PCP](https://psychonautwiki.org/wiki/3-MeO-PCP)
- [3-HO-PCP](https://psychonautwiki.org/wiki/3-HO-PCP)
- [PCP](https://psychonautwiki.org/wiki/PCP)

## External links

- [3-HO-PCE (Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=968)

### Discussion

- [The Big & Dandy 3-HO-PCE Thread (Bluelight)](http://bluelight.org/vb/threads/812314-The-Big-amp-Dandy-3-HO-PCE-Thread)
- [Interview with a Ketamine Chemist (VICE)](https://web.archive.org/web/20170111011440*/https://www.vice.com/en_us/article/interview-with-ketamine-chemist-704-v18n2)

## Literature

- Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. [https://doi.org/10.1002/dta.1620](https://doi.org/10.1002/dta.1620)

## References
1. ↑ 1.0 1.1 Morris, H., Wallach, J. (July 2014).["From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE"](https://onlinelibrary.wiley.com/doi/10.1002/dta.1620).*Drug Testing and Analysis*.**6**(7–8): 614–632.[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/dta.1620](//doi.org/10.1002%2Fdta.1620).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[1942-7603](//www.worldcat.org/issn/1942-7603).
2. ↑ 2.0 2.1 2.2 Kalir, A., Maayani, S., Rehavi, M., Elkavets, R., Pri-Bar, I., Buchman, O., Sokolovsky, M. (20 June 1978).["ChemInform Abstract: STRUCTURE-ACTIVITY RELATIONSHIP OF SOME PHENCYCLIDINE DERIVATIVES- IN VIVO STUDIES IN MICE"](https://onlinelibrary.wiley.com/doi/10.1002/chin.197825192).*Chemischer Informationsdienst*.**9**(25).[doi](http://en.wikipedia.org/wiki/Digital_object_identifier):[10.1002/chin.197825192](//doi.org/10.1002%2Fchin.197825192).[ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number)[0009-2975](//www.worldcat.org/issn/0009-2975).
3. ↑ " [(ACMD) Methoxetamine Report (2012)](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119087/methoxetamine2012.pdf) " (PDF). UK Home Office. 2012-10-18. p. 14. Retrieved 2015-06-24.
4. ↑ 3-HO-PCE (Tripsit) | [https://wiki.tripsit.me/wiki/3-HO-PCE](https://wiki.tripsit.me/wiki/3-HO-PCE)
5. ↑ ["Anlage NpSG"](https://www.gesetze-im-internet.de/npsg/anlage.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
6. ↑ ["Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes"](http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf)(PDF).*Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27*(in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
7. ↑ ["§ 4 NpSG"](https://www.gesetze-im-internet.de/npsg/__4.html)(in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
8. ↑ ["Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html)(in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
9. ↑ Cumhurbaşkanı Kararı CK Karar Sayısı : 1335 | [https://resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf](https://resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf)
10. ↑ [The Misuse of Drugs Act 1971 (Amendment) Order 2013](https://www.legislation.gov.uk/uksi/2013/239/introduction/made)NewPP limit report Cached time: 20251218075015 Cache expiry: 1209600 Dynamic content: false Complications: [] [SMW] In‐text annotation parser time: 0.039 seconds CPU time usage: 0.278 seconds Real time usage: 0.502 seconds Preprocessor visited node count: 1390/1000000 Post‐expand include size: 88717/2097152 bytes Template argument size: 13350/2097152 bytes Highest expansion depth: 12/40 Expensive parser function count: 0/100 Unstrip recursion depth: 0/20 Unstrip post‐expand size: 10920/5000000 bytes Lua time usage: 0.140/7 seconds Lua virtual size: 8.59 MB/50 MB Lua estimated memory usage: 0 bytes ExtLoops count: 11Transclusion expansion time report (%,ms,calls,template) 100.00% 382.796 1 -total 19.33% 73.979 2 Template:Cite_journal 17.50% 66.984 1 Template:SubstanceBox/3-HO-PCE 16.31% 62.450 1 Template:SubstanceBox 15.71% 60.137 4 Template:Cite_web 15.58% 59.634 1 Template:Distinguish 14.40% 55.106 1 Template:Hatnote 12.11% 46.338 1 Template:Citation_needed 10.29% 39.384 1 Template:Fix 9.57% 36.641 2 Template:Category_handler`,
  "tripsit-factsheets": `# 3-HO-PCE
*Source: https://tripbot.tripsit.me/api/tripsit/getDrug/3-ho-pce*

## Classification
- **Categories:** dissociative, research-chemical, habit-forming, tentative
- **Also known as:** 3hopce

## Dosage

### Oral
- **Common:** 5-10mg
- **Light:** 2-5mg
- **Strong:** 10-15mg

## Duration
- **Onset:** 20-40 minutes
- **Duration:** 3-4 hours
- **After Effects:** 2 hours
`,
  "wikipedia": `# 3-HO-PCP
*Source: https://en.wikipedia.org/wiki/3-HO-PCP*

3-Hydroxyphencyclidine (3-HO-PCP) is a dissociative of the arylcyclohexylamine class related to phencyclidine (PCP) that has been sold online as a designer drug.

## Pharmacology

3-HO-PCP acts as a high-affinity uncompetitive antagonist of the NMDA receptor via the dizocilpine (MK-801) site (Ki = 30 nM). It has much higher affinity than PCP for this site (Ki = 250 nM, for comparison; 8-fold difference). The drug also has high affinity for the μ-opioid receptor (MOR) (Ki = 39–60 nM) in animal test subjects, the κ-opioid receptor (KOR) (Ki = 140 nM), and the sigma σ1 receptor (Ki = 42 nM; IC50 = 19 nM), whereas it has only low affinity for the δ-opioid receptor (Ki = 2,300 nM). The high affinity of 3-HO-PCP for opioid receptors is unique among arylcyclohexylamines and is in contrast to PCP, which has only very low affinity for the MOR (Ki = 11,000–26,000 nM; 282- to 433-fold difference) and the other opioid receptors (Ki = 4,100 nM for the KOR and 73,000 nM for the DOR).
Although it was hypothesized that 3-HO-PCP might be a metabolite of PCP in humans, there is no evidence that this is the case. 3-HO-PCP is a metabolite of 3-MeO-PCP.

## Chemistry

3-HO-PCP is an arylcyclohexylamine. Close analogues of 3-HO-PCP include PCP, 3-MeO-PCP, 4-MeO-PCP, 3-MeO-PCMo, and somewhat more distantly ketamine, methoxyketamine, 3-MeO-PCE, methoxetamine and dimetamine.

## History

3-HO-PCP was mentioned by a chemist under the pseudonym "John Q. Beagle" in 1999 in a post on The Hive. The psychoactive effects of 3-HO-PCP have been described by Bluelight users even before its availability as a research chemical in 2009.

## Society and culture

### Legal status

On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the "harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971)", despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including 3-HO-PCP.
3-HO-PCP is banned in Sweden and Switzerland.
`,
};
